Today on Bloomberg radio's "Taking Stock" a drug called Lymphoseek was discussed. The drug is currently in Phase 3 trials. I have not purchased this stock but am investigating further.
One article I found at medcitynews.com (http://www.medcitynews.com/2010/04/neoprobe-to-file-for-fda-approval-of-lymphoseek-this-summer/) contains the following information:
"The company has said that within two years of Lymphoseek’s release it would have more than half the market share, thanks to its agreement with Cardinal Health to distribute the drug once it’s ready."
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment